How MCAS Causes or Exacerbates POTS Symptoms
Mast cell activation syndrome (MCAS) can trigger or worsen POTS symptoms through release of vasoactive mediators—particularly histamine, prostaglandins, and leukotrienes—that cause vasodilation, blood pressure instability, and hyperadrenergic responses, though the mechanistic evidence remains limited and largely theoretical. 1
Proposed Pathophysiological Mechanisms
The connection between MCAS and POTS involves several overlapping pathways, though experimental evidence is still evolving:
Mast Cell Mediator Effects on Cardiovascular Function
When mast cells degranulate, they release inflammatory molecules including:
- Histamine - causes vasodilation and increased vascular permeability, reducing venous return
- Prostaglandins - contribute to blood pressure instability
- Heparin and cytokines - promote systemic inflammation affecting vascular tone 1
These mediators directly impact the cardiovascular system by causing blood vessel dilation and pooling, which forces compensatory tachycardia when standing—the hallmark of POTS 2.
Hyperadrenergic Response Pattern
Patients with both MCAS and POTS often exhibit a characteristic hyperadrenergic phenotype with:
- Excessive orthostatic tachycardia (heart rate increases of 30-50+ bpm on standing)
- Paradoxical blood pressure increases rather than decreases
- Exaggerated Valsalva phase IV overshoot (50 vs 17 mmHg in controls)
- Elevated systolic pressure during orthostatic challenge 2
This suggests mast cell mediators may trigger excessive sympathetic nervous system activation, creating a vicious cycle of symptoms 1, 2.
Clinical Presentation and Symptom Overlap
Distinguishing Features
Patients with MCAS-associated POTS typically present with additional non-orthostatic symptoms beyond typical POTS complaints:
- Flushing episodes (key distinguishing feature)
- Gastrointestinal symptoms: diarrhea, nausea, vomiting, abdominal cramping 3
- Cutaneous manifestations: urticaria, pruritus, angioedema 3
- Respiratory symptoms: shortness of breath, nasal congestion 3
- Neurologic complaints: headache, brain fog, poor concentration 3
- Allergic-type reactions without clear IgE triggers 4
Triggering Events
Common triggers that activate both conditions include:
- Prolonged standing or exercise
- Temperature extremes
- Emotional stress
- Premenstrual cycle
- Meals
- Physical trauma or mechanical stimuli 1, 2
Evidence Quality and Clinical Reality
The Evidence Gap
Critical limitation: While 42-66% of POTS patients show laboratory markers suggesting mast cell activation 4, recent systematic reviews found no studies meeting strict diagnostic criteria for both conditions simultaneously 5. The 2025 AGA guideline explicitly states the biological link remains "limited and evolving" with only "theoretical explanations" 1.
Most published associations are based on:
- Patient self-report rather than validated diagnostic criteria
- Single abnormal laboratory values (not definitive for MCAS)
- Retrospective surveys with selection bias 1
Laboratory Findings in Clinical Practice
When MCAS is suspected in POTS patients with additional symptoms, the most frequently elevated markers are:
- Prostaglandins (most common finding) 4
- Plasma histamine or urinary methylhistamine 4, 2
- Serum tryptase (though baseline levels often normal; requires measurement during symptomatic episodes within 30-120 minutes) 3
Important caveat: Solitary abnormal findings are not diagnostic of MCAS and should not drive treatment decisions alone 4.
Clinical Approach
When to Suspect MCAS in POTS Patients
Test for mast cell activation only when patients present with characteristic MCAS symptoms (flushing, allergic-type reactions, GI symptoms, skin manifestations) in addition to orthostatic intolerance—not as universal screening 1.
Blood Pressure Patterns as a Clue
Unlike typical POTS where blood pressure remains stable or drops slightly:
- MCAS-associated POTS often shows blood pressure increases on standing
- Systolic BP may rise 10-20 mmHg rather than remaining stable
- This hyperadrenergic pattern suggests mast cell mediator involvement 2
Treatment Implications
Critical warning: Beta-blockers, commonly used for POTS, should be used with extreme caution or avoided in MCAS-associated POTS, as they may worsen mast cell mediator release 2.
Instead, consider mast cell-directed therapies when MCAS is confirmed:
- H1 and H2 antihistamines (combined therapy)
- Leukotriene receptor antagonists (montelukast)
- Mast cell stabilizers (cromolyn sodium)
- COX inhibitors for prostaglandin production 3, 6
Common Pitfalls
Over-diagnosis: Not every POTS patient with GI symptoms has MCAS—these symptoms overlap with many DGBI conditions 1
Relying on single lab values: One elevated mediator level does not confirm MCAS diagnosis 4
Assuming causation: The association may reflect shared underlying pathophysiology (like connective tissue abnormalities in hEDS) rather than direct causation 1
Universal testing: Current evidence does not support routine MCAS screening in all POTS patients 1
The relationship between MCAS and POTS remains an area requiring rigorous research with validated diagnostic criteria for both conditions 5, 7.